Table 1 Diagnostic lipid signatures in cancers
From: How cancer cells remodel lipid metabolism: strategies targeting transcription factors
Cancer type | Control samples | Cancer samples | Biofluid | Altered lipids | References |
|---|---|---|---|---|---|
Hepatocellular carcinoma | 14 | 23 | Plasma | SFA (12:0, 14:0, 15:0, 16:0, 20:0, 22:0) MUFA (16:1n-7, 17:1n-9, 18:1n-9, 22:1n-9) PUFA (18:2n-6, 20:4n-6, 22:5n-3) | [42] |
42 | 42 | Tissue | SFA (14:0, 15:0) MUFA (14:1, 16:1n-7, 17:1n-9, 18:1n-9, 24:1n-9) PUFA (18:2n-6, 20:3n-6, 22:2n-6, 22:4n-6, 22:5n-3, 22:6n-3) | ||
Bladder cancer | 31 | 31 | Tissue | SFA (4:0, 6:0, 7:0, 8:0, 16:0) MUFA (16:1n-7, 20:1n-9) PUFA (18:2n-6, 18:3n-3, 18:4n-3 20:1n-9, 20:2n-6, 20:5n-3, 22:2n-6, 22:3n-3, 22:5n-3, 22:6n-3), CHO | [43] |
Lymphoma | 29 | 47 | Plasma | SFA (16:0) MUFA (18:1n-9) PUFA (18:2n-6, 20:5n-3, 22:4n-6, 22:6n-3) | [44] |
Colorectal cancer | 12 | 17 | Plasma | SFA (16:0) MUFA (18:1n-7, 18:1n-9) PUFA (18:2n-6, 20:3n-6) TG, CHO | [9] |
20 | 20 | Tissue | SFA (14:0, 18:0) MUFA (16:1, 18:1) PUFA (18:2, 20:4, 20:5, 22:2, 22:3) TG, CHO | [10] | |
25 | 25 | Tissue | SFA (16:0, 18:0) MUFA (16:1, 18:1) PUFA (18:3, 20:4, 20:5, 22:6) TG, CHO | [11] | |
Lymphoblastic leukemia | 22 | 80 | Plasma | TG, LDL | [13] |
Prostate cancer | 14 | 20 | Plasma | SFA (18:0) PUFA (18:2n-6, 20:4) TG, CHO | [12] |